GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance-Reference-Cited by-同舟云学术

GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance

Published:2019-08 Issue:8 Volume:57 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Huh Hee Jae¹,Kim Su-Young²,Shim Hyang Jin³,Kim Dae Hun²,Yoo In Young¹,Kang On-Kyun¹,Ki Chang-Seok⁴,Shin So Youn⁵,Jhun Byung Woo²,Shin Sung Jae⁶⁷⁸,Daley Charles L.⁹¹⁰,Koh Won-Jung²,Lee Nam Yong¹

Affiliation:

1. Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

2. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

3. Center for Clinical Medicine, Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, South Korea

4. Green Cross Genome, Yongin, South Korea

5. Korean Institute of Tuberculosis, Cheongju, South Korea

6. Department of Microbiology, Yonsei University College of Medicine, Seoul, South Korea

7. Institute for Immunology and Immunological Disease, Yonsei University College of Medicine, Seoul, South Korea

8. Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea

9. Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado, USA

10. Department of Medicine, University of Colorado, Aurora, Colorado, USA

Abstract

We evaluated the GenoType NTM-DR (NTM-DR) line probe assay for identifying Mycobacterium avium complex (MAC) species and Mycobacterium abscessus subspecies and for determining clarithromycin and amikacin resistance. Thirty-eight reference strains and 145 clinical isolates (58 MAC and 87 M. abscessus isolates), including 54 clarithromycin- and/or amikacin-resistant strains, were involved.

Funder

National Research Foundation of Korea

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.00516-19

Reference46 articles.

1. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases

2. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)

3. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis